Edward E. Kadel

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

Sanjeev Mariathasan, Shannon J. Turley, Dorothee Nickles et al. · Nature · 2018 · 5.5K citations

Life Sciences, Immunology, Oncology +16

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

Arjun Vasant Balar, Matthew D. Galsky, Jonathan E. Rosenberg et al. · The Lancet · 2016 · 2.2K citations · Full text

Medicine, Oncology, Pharmacology +11

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

Thomas Powles, Ignacio Durán, Michiel S. van der Heijden et al. · The Lancet · 2017 · 1.4K citations · Full text

Medicine, Oncology, Pharmacotherapy +12

High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade

Kobe Yuen, Lifen Liu, Vinita Gupta et al. · Nature Medicine · 2020 · 439 citations · Full text

Life Sciences, Immunology, Oncology +16

Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial

Thomas Powles, Kobe Yuen, Silke Gillessen et al. · Nature Medicine · 2022 · 242 citations · Full text

Medicine, Oncology, Pharmacotherapy +16